Revumenib is a small molecule commercialized by Syndax Pharmaceuticals, with a leading Pre-Registration program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 16 clinical trials, of which 12 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Revumenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Revumenib is expected to reach an annual total of $603 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Revumenib Overview

Revumenib citrate (SNDX-5613) is under development for the treatment of genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene such as relapsed and refractory acute lymphoblastic leukemia, relapsed and refractory acute myelobalstic leukemia and unresectable metastatic microsatellite stable colorectal cancer. It is administered through oral route in the form of capsules. The drug candidate acts by targeting interaction of menin with the mixed lineage leukemia (MLL) protein.

Syndax Pharmaceuticals Overview

Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The company’s product portfolio includes SNDX-5613, a novel orally menin-MLL1 inhibitor used for the treatment of MLLr or mNPM1 acute leukemias; and SNDX-6352 (Axatilimab), a colony stimulating factor 1 receptor (CSF-1R) to treat chronic graft versus host disease (cGVHD). It is also evaluating entinostat (SNDX-275), a class I HDAC inhibitor against multiple solid tumors. Syndax product candidate are also used for the treatment of non-small cell lung cancer and melanoma, ovarian cancer and other indications. Syndax is headquartered in Waltham, Massachusetts, the US.
The operating loss of the company was US$151.8 million in FY2022, compared to an operating profit of US$26.2 million in FY2021. The net loss of the company was US$149.3 million in FY2022, compared to a net profit of US$24.9 million in FY2021.

For a complete picture of Revumenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.